[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 27056
1. Szeto DP, Griffin KJ, Kimelman D: HrT is required for cardiovascular development in zebrafish. Development; 2002 Nov;129(21):5093-101
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HrT is required for cardiovascular development in zebrafish.
  • The recently identified zebrafish T-box gene hrT is expressed in the developing heart and in the endothelial cells forming the dorsal aorta.
  • Orthologs of hrT are expressed in cardiovascular cells from Drosophila to mouse, suggesting that the function of hrT is evolutionarily conserved.
  • The role of hrT in cardiovascular development, however, has not thus far been determined in any animal model.
  • Using morpholino antisense oligonucleotides, we show that zebrafish embryos lacking hrT function have dysmorphic hearts and an absence of blood circulation.
  • Although the early events in heart formation were normal in hrT morphant embryos, subsequently the hearts failed to undergo looping, and late onset defects in chamber morphology and gene expression were observed.
  • In particular, we found that the loss of hrT function led to a dramatic upregulation of tbx5, a gene required for normal heart morphogenesis.
  • Conversely, we show that overexpression of hrT causes a significant downregulation of tbx5, indicating that one key role of hrT is to regulate the levels of tbx5.
  • Secondly, we found that HrT is required to inhibit the expression of the blood lineage markers gata1 and gata2 in the most posterior lateral plate mesoderm.
  • Finally, we show that HrT is required for vasculogenesis in the trunk, leading to similar vascular defects to those observed in midline mutants such as floating head. hrT expression in the vascular progenitors depends upon midline mesoderm, indicating that this expression is one important component of the response to a midline-derived signal during vascular morphogenesis.
  • [MeSH-minor] Animals. Gene Expression Regulation, Developmental. Heart Defects, Congenital / embryology. Heart Defects, Congenital / genetics. Hematopoiesis / genetics. Hematopoiesis / physiology. Homeodomain Proteins / genetics. Homeodomain Proteins / physiology. Humans. In Situ Hybridization. Mice. Mutation. Oligodeoxyribonucleotides, Antisense / genetics. Oligodeoxyribonucleotides, Antisense / pharmacology. Recombinant Fusion Proteins / genetics. Transcription Factors / genetics. Transcription Factors / physiology

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12397116.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / F32 HD08725; United States / PHS HHS / / T32 07312
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Recombinant Fusion Proteins; 0 / T-Box Domain Proteins; 0 / T-box transcription factor 5; 0 / TBX20 protein, human; 0 / Tbx20 protein, mouse; 0 / Transcription Factors; 0 / Zebrafish Proteins; 0 / flh protein, zebrafish; 0 / tbx20 protein, zebrafish
  •  go-up   go-down


2. Maslin JS, Mansouri K, Dorairaj SK: HRT for the Diagnosis and Detection of Glaucoma Progression. Open Ophthalmol J; 2015;9:58-67

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HRT for the Diagnosis and Detection of Glaucoma Progression.
  • Confocal scanning laser ophthalmoscopy through the Heidelberg Retina Tomograph (HRT) provides a rapid, safe, noncontact, and noninvasive imaging of the optic disc in three-dimensions, and provides precise detailed information about the optic disc beyond that which the clinical exam can measure.
  • The HRT I was developed for research purposes only and was not used clinically.
  • The HRT II was developed to be user-friendly, more rapid, and was used as an adjunct to clinical examination in the detection and progression of glaucoma.
  • One of the main pitfalls of the HRT II was that it was operator-dependent.
  • The HRT III was developed to be operator-independent.
  • Numerous studies have compared these two methods of analysis, with the conclusion that the Glaucoma Probability Score provides a higher sensitivity and a lower specificity than the Moorsfield Regression Analysis, which may indicate that it has potential as a screening test for glaucoma.
  • However, there is no consensus on the use of the Glaucoma Probability Score as a screening test for glaucoma.
  • While HRT data may be useful as a clinical adjunct in the screening and diagnosis of glaucoma, it should ultimately only be used to support clinical examination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26069518.001).
  • [ISSN] 1874-3641
  • [Journal-full-title] The open ophthalmology journal
  • [ISO-abbreviation] Open Ophthalmol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC4460217
  • [Keywords] NOTNLM ; Glaucoma / Heidelberg retina tomograph / retinal nerve fiber layer / topographic change analysis
  •  go-up   go-down


3. Compston JE: The risks and benefits of HRT. J Musculoskelet Neuronal Interact; 2004 Jun;4(2):187-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risks and benefits of HRT.
  • For many years hormone replacement therapy (HRT) was regarded as the gold standard for treatment of osteoporosis.
  • The current consensus is that HRT is no longer regarded as a front-line option for prevention of osteoporotic fractures and that its use for this purpose should be restricted to women with osteoporosis who have menopausal symptoms and to older women who are intolerant of other therapies and/or express a strong preference for HRT despite being informed about potential adverse effects.
  • Nevertheless, the mechanisms by which estrogen exerts its beneficial skeletal effects remain a major area of research that has important implications for the development of novel therapies.
  • [MeSH-major] Breast Neoplasms / epidemiology. Cardiovascular Diseases / epidemiology. Estrogen Replacement Therapy / adverse effects. Osteoporosis / drug therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15615123.001).
  • [ISSN] 1108-7161
  • [Journal-full-title] Journal of musculoskeletal & neuronal interactions
  • [ISO-abbreviation] J Musculoskelet Neuronal Interact
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 25
  •  go-up   go-down


Advertisement
4. Escalante CG, Mora SQ, Bola├▒os LN: Hormone replacement therapy reduces lipid oxidation directly at the arterial wall: A possible link to estrogens' cardioprotective effect through atherosclerosis prevention. J Midlife Health; 2017 Jan-Mar;8(1):11-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone replacement therapy reduces lipid oxidation directly at the arterial wall: A possible link to estrogens' cardioprotective effect through atherosclerosis prevention.
  • Could it be that the potential cardioprotective effect observed in women receiving hormone replacement therapy (HRT) is modulated by estrogen's capacity to decrease LDL oxidation in the vascular wall and thus decrease atherosclerotic foam cells?
  • Malondialdehyde (MDA) was measured directly on the vascular extract to determine lipid oxidative levels and HRTs' effect.
  • ANOVA (<i>P</i> < 0.05), with a <i>post hoc</i> Bonferroni corrective <i>t</i>-test, showed that both Group 1 and 2 have statistically significant lower levels of MDA than Group 3.
  • Renal tissue showed less oxidative damage in the HRT groups, while hepatic tissue showed an inverse behavior with less lipid oxidation in the placebo group.
  • TAS decreased with oophorectomy in all groups but decreased less in both groups that received HRT compared to placebo (<i>P</i> < 0.05).
  • CONCLUSION: HRT significantly reduces lipid oxidation directly in the arterial wall.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2012 Oct 09;345:e6409 [23048011.001]
  • [Cites] Menopause. 1998 Spring;5(1):16-23 [9689190.001]
  • [Cites] EMBO Mol Med. 2010 Mar;2(3):79-89 [20201031.001]
  • [Cites] FEBS Lett. 1987 Mar 9;213(1):9-14 [3030811.001]
  • [Cites] Endocrinology. 1999 Jul;140(7):3372-82 [10385435.001]
  • [Cites] Climacteric. 2015 Jun;18(3):379-88 [25236970.001]
  • [Cites] Life Sci. 2015 Jun 1;130:57-65 [25818184.001]
  • [Cites] Immunobiology. 2013 Nov;218(11):1376-84 [23886694.001]
  • [Cites] Toxicol Int. 2013 Jan;20(1):43-7 [23833437.001]
  • [Cites] Int J Clin Exp Med. 2015 May 15;8(5):8197-203 [26221393.001]
  • [Cites] Hepat Mon. 2015 Feb 09;15(2):e22633 [25788954.001]
  • [Cites] Int J Clin Exp Med. 2015 Jun 15;8(6):8648-60 [26309517.001]
  • [Cites] J Neuroinflammation. 2015 Dec 18;12:238 [26683475.001]
  • [Cites] Physiol Rep. 2015 Apr;3(4):null [25902787.001]
  • [Cites] Am J Physiol. 1998 Jun;274(6 Pt 1):E1002-8 [9611149.001]
  • [Cites] Clinics (Sao Paulo). 2010 Jun;65(8):803-7 [20835559.001]
  • [Cites] Circulation. 2011 Mar 22;123(11):1243-62 [21325087.001]
  • [Cites] BMJ. 2005 Sep 3;331(7515):467-8 [16141136.001]
  • [Cites] Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1169-78 [25209863.001]
  • [Cites] In Vivo. 2014 Nov-Dec;28(6):1097-100 [25398805.001]
  • [Cites] Ther Adv Neurol Disord. 2009 Jan;2(1):31-49 [19890493.001]
  • [Cites] BMC Pharmacol. 2007 Mar 04;7:3 [17335585.001]
  • [Cites] Cancer Res. 1980 Apr;40(4):1091-6 [7357540.001]
  • [Cites] BMC Clin Pathol. 2002 Aug 28;2(1):3 [12197944.001]
  • [Cites] Am J Epidemiol. 2006 Apr 1;163(7):589-99 [16484450.001]
  • [Cites] Circ Res. 2003 Jul 25;93(2):170-7 [12816884.001]
  • [Cites] J Clin Pharmacol. 1995 Sep;35(9 Suppl):18S-24S [8530713.001]
  • [Cites] Prog Cardiovasc Dis. 1995 Nov-Dec;38(3):199-210 [7494882.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Oct;77(4):1095-7 [8408459.001]
  • [Cites] Maturitas. 2001 Apr 20;38(2):165-70 [11306205.001]
  • [Cites] Nature. 2011 May 19;473(7347):317-25 [21593864.001]
  • [Cites] Methods Mol Biol. 1998;108:101-6 [9921519.001]
  • [Cites] Clin Chim Acta. 2006 Jul 15;369(1):73-7 [16472795.001]
  • [Cites] J Gen Intern Med. 2004 Jul;19(7):791-804 [15209595.001]
  • [Cites] JAMA. 2013 Oct 2;310(13):1353-68 [24084921.001]
  • [Cites] Circ Res. 2005 Nov 11;97(10):1046-54 [16195479.001]
  • [Cites] Life Sci. 2016 May 1;152:244-8 [26596563.001]
  • [Cites] Int J Prev Med. 2013 Jun;4(6):624-30 [23930179.001]
  • [Cites] J Steroid Biochem Mol Biol. 2014 Jul;142:68-75 [23851166.001]
  • [Cites] World J Cardiol. 2014 Jun 26;6(6):462-77 [24976919.001]
  • [Cites] Arch Intern Med. 1994 Jun 27;154(12):1333-9 [8002685.001]
  • [Cites] Lab Anim. 2004 Jan;38(1):44-9 [14979987.001]
  • [Cites] Climacteric. 2013 Feb;16(1):104-10 [22530644.001]
  • (PMID = 28458474.001).
  • [ISSN] 0976-7800
  • [Journal-full-title] Journal of mid-life health
  • [ISO-abbreviation] J Midlife Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Atherosclerosis / hormone replacement therapy / oxidative stress
  •  go-up   go-down


5. Sismondi P, Biglia N, Giai M, Ponzone R, Roagna R, Sgro L, Campagnoli C: HRT, breast and endometrial cancers: strategies and intervention options. Maturitas; 1999 Aug 16;32(3):131-9
MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HRT, breast and endometrial cancers: strategies and intervention options.
  • The demand for hormone replacement therapy (HRT) by women who enter the menopause is rapidly increasing in all developed countries.
  • The concern that HRT may enhance morbidity and mortality from malignant diseases still limits the widespread adoption of hormonal treatments.
  • Overall, epidemiological data on cancer incidence and HRT are reassuring, although long-term or inappropriate therapies may slightly increase the risk of developing malignant diseases.
  • Many commercial hormonal compounds are currently available and the safest HRT regimen with regard to cancer risk must be identified.
  • It is equally important that the best strategies for breast and endometrial surveillance in women commencing HRT be outlined, bearing in mind that the diffusion of hormonal therapies may be halted by unnecessary medical interventions.
  • [MeSH-major] Breast Neoplasms / chemically induced. Endometrial Neoplasms / chemically induced. Hormone Replacement Therapy / adverse effects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10515669.001).
  • [ISSN] 0378-5122
  • [Journal-full-title] Maturitas
  • [ISO-abbreviation] Maturitas
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] IRELAND
  • [Number-of-references] 33
  •  go-up   go-down


6. Renard JP, Giraud JM: [Glaucoma - structural imagery: HRT, GDX, OCT]. J Fr Ophtalmol; 2006 Jan;29(1):64-73
MedlinePlus Health Information. consumer health - Glaucoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glaucoma - structural imagery: HRT, GDX, OCT].
  • [Transliterated title] Glaucomes. Imagerie de la structure: HRT, GDx et OCT.
  • Confocal scanning laser tomography (HRT), scanning laser polarimetry (GDx VCC), and optical coherence tomography provide quantitative data of the retinal fiber layer and optic nerve head.
  • [MeSH-major] Glaucoma / diagnosis. Lasers. Microscopy, Confocal. Tomography, Optical Coherence

  • Genetic Alliance. consumer health - Glaucoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465127.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal franc╠žais d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 42
  •  go-up   go-down


7. Monda V, Salerno M, Fiorenzo M, Villano I, Viggiano A, Sessa F, Triggiani AI, Cibelli G, Valenzano A, Marsala G, Zammit C, Ruberto M, Messina G, Monda M, De Luca V, Messina A: Role of Sex Hormones in the Control of Vegetative and Metabolic Functions of Middle-Aged Women. Front Physiol; 2017;8:773

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of Sex Hormones in the Control of Vegetative and Metabolic Functions of Middle-Aged Women.
  • The aim of this study was to determining whether healthy, obese menopausal women underwent HRT treatment, showed changes in their REE, autonomic asset, and assessment of oxidative stress in comparison with obese pre- and post-menopausal women.
  • <b>Methodology:</b> In this study, we measured the body composition, the REE, the oxidative stress, the diet assimilation, and the autonomic nervous system activity in three groups: pre-menopause women (<i>n</i> = 50), post-menopause women following hormone-replacement therapy (HRT; <i>n</i> = 50), and post-menopause women not following HRT (<i>n</i> = 50).
  • <b>Results:</b> In the group with HRT a significant increase of the sympathetic activity and REE was described.
  • <b>Conclusion:</b> The study highlights the importance of the HRT-related physiological changes that influence body weight in menopause women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1992 Dec 15;117(12):1016-37 [1443971.001]
  • [Cites] Arch Belg. 1989;47(1-4):118-22 [2610550.001]
  • [Cites] Neuropeptides. 2006 Oct;40(5):357-63 [17010428.001]
  • [Cites] Behav Neurosci. 1984 Aug;98(4):674-85 [6466443.001]
  • [Cites] Obes Res. 2003 Jan;11(1):2-4 [12529478.001]
  • [Cites] BJOG. 2010 Mar;117(4):488-92 [20105164.001]
  • [Cites] Physiol Behav. 1972 Jul;9(1):79-82 [4673098.001]
  • [Cites] Chem Res Toxicol. 2002 Apr;15(4):512-9 [11952337.001]
  • [Cites] J Cell Physiol. 2016 Jun;231(6):1385-91 [26626779.001]
  • [Cites] Clin Physiol Funct Imaging. 2017 Mar;37(2):162-167 [26211739.001]
  • [Cites] Hum Exp Toxicol. 2002 Feb;21(2):71-5 [12102499.001]
  • [Cites] J Clin Invest. 1998 Sep 1;102(5):1035-40 [9727072.001]
  • [Cites] Chemosphere. 2014 Jan;94:62-9 [24112656.001]
  • [Cites] Front Psychol. 2014 Sep 08;5:997 [25250003.001]
  • [Cites] Curr Pharm Des. 2013;19(15):2765-70 [23092325.001]
  • [Cites] J Mol Med (Berl). 1996 Jun;74(6):297-312 [8862511.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):669-70 [7637741.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3312-7 [15741268.001]
  • [Cites] JAMA. 1998 Aug 19;280(7):605-13 [9718051.001]
  • [Cites] Chem Res Toxicol. 1999 Feb;12(2):204-13 [10027800.001]
  • [Cites] J Nutr Sci Vitaminol (Tokyo). 2000 Dec;46(6):309-15 [11227803.001]
  • [Cites] Cardiovasc Diabetol. 2011 Jul 14;10 :62 [21756303.001]
  • [Cites] Am J Cardiol. 2004 Feb 1;93(3):381-5 [14759400.001]
  • [Cites] Eur J Clin Invest. 1995 Nov;25(11):826-32 [8582447.001]
  • [Cites] Eur J Clin Nutr. 2007 Dec;61(12):1442-4 [17311051.001]
  • [Cites] Int J Psychophysiol. 2016 May;103:79-87 [25660308.001]
  • [Cites] Neuroscience. 2010 Mar 17;166(2):416-21 [20045451.001]
  • [Cites] Auton Neurosci. 2012 Aug 16;169(2):102-6 [22682704.001]
  • [Cites] Neurol Res Int. 2013;2013:639280 [23691314.001]
  • [Cites] Clin Nutr. 2008 Aug;27(4):657-9 [18514973.001]
  • [Cites] Physiol Behav. 1979 Mar;22(3):583-93 [379889.001]
  • [Cites] Stem Cell Res Ther. 2014 Jan 09;5(1):4 [24405848.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S8-17 [10997600.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):344-8 [11232022.001]
  • [Cites] J Clin Epidemiol. 1994 Mar;47(3):283-91 [8138838.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):67-73 [10963620.001]
  • [Cites] Ann Intern Med. 1995 Nov 1;123(9):673-5 [7574222.001]
  • [Cites] J Appl Physiol (1985). 1993 Dec;75(6):2514-20 [8125870.001]
  • [Cites] Fertil Steril. 1995 Nov;64(5):963-8 [7589642.001]
  • [Cites] Stem Cell Res. 2013 Nov;11(3):1037-44 [23954692.001]
  • [Cites] Obes Res. 2001 Feb;9(2):78-85 [11316350.001]
  • [Cites] Lancet. 1994 Jan 29;343(8892):269-70 [7905101.001]
  • [Cites] Am J Physiol. 1991 Dec;261(6 Pt 2):R1418-23 [1750566.001]
  • [Cites] J Diabetes Complications. 2009 Mar-Apr;23(2):119-23 [18413209.001]
  • [Cites] BMJ. 1997 Jul 19;315(7101):149-53 [9251544.001]
  • [Cites] Obes Surg. 2010 Mar;20(3):332-9 [19862582.001]
  • [Cites] Int J Obes Relat Metab Disord. 1999 Aug;23(8):793-800 [10490779.001]
  • [Cites] Maturitas. 1999 Jan 4;31(2):137-42 [10227007.001]
  • [Cites] Ann Intern Med. 1993 Mar 15;118(6):436-47 [8439119.001]
  • [Cites] Chem Res Toxicol. 1998 Sep;11(9):1105-11 [9760286.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Aug;81(4-5):327-32 [12361722.001]
  • [Cites] Circulation. 2001 Jun 19;103(24):2903-8 [11413078.001]
  • [Cites] Nutr Neurosci. 2006 Jun-Aug;9(3-4):141-5 [17176636.001]
  • [Cites] N Engl J Med. 1988 Feb 25;318(8):467-72 [3340128.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1549-56 [9141548.001]
  • [Cites] Peptides. 2008 Jan;29(1):120-6 [18053616.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1083:129-52 [17148737.001]
  • [Cites] Obstet Gynecol Int. 2013;2013:209812 [23840215.001]
  • [Cites] Circulation. 1996 Mar 1;93(5):1043-65 [8598068.001]
  • [Cites] Monaldi Arch Chest Dis. 2007 Jun;68(2):87-95 [17886769.001]
  • [Cites] Int J Obes Relat Metab Disord. 1999 Jul;23(7):715-22 [10454105.001]
  • [Cites] Vascul Pharmacol. 2013 Jan;58(1-2):127-33 [23070057.001]
  • [Cites] Metabolism. 2001 Mar;50(3):265-9 [11230776.001]
  • [Cites] Oxid Med Cell Longev. 2014;2014:131024 [25197428.001]
  • [Cites] Saudi Med J. 2013 Feb;34(2):135-41 [23396458.001]
  • [Cites] Brain Res Bull. 1993;32(6):689-92 [8221168.001]
  • [Cites] J Lipid Res. 1998 Nov;39(11):2111-8 [9799796.001]
  • [Cites] Antioxid Redox Signal. 2000 Winter;2(4):903-17 [11213491.001]
  • [Cites] J Basic Clin Physiol Pharmacol. 2016 Nov 1;27(6):611-616 [27665420.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:203-32 [8725388.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):427-33 [10688862.001]
  • [Cites] J Clin Endocrinol Metab. 2012 Apr;97(4):1159-68 [22344196.001]
  • [Cites] Metabolism. 1988 Mar;37(3):287-301 [3278194.001]
  • [Cites] J Sports Sci. 2014;32(1):46-52 [23876006.001]
  • [Cites] Am J Physiol. 1993 Mar;264(3 Pt 1):E450-5 [8460693.001]
  • [Cites] Psychiatry Investig. 2008 Dec;5(4):203-8 [20046338.001]
  • [Cites] Regul Pept. 2007 Mar 1;139(1-3):39-44 [17134769.001]
  • (PMID = 29046646.001).
  • [ISSN] 1664-042X
  • [Journal-full-title] Frontiers in physiology
  • [ISO-abbreviation] Front Physiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; assessment of oxidative stress / autonomic nervous system / body composition / hormone-replacement therapy / resting energy expenditure
  •  go-up   go-down


8. Persico N, Mancini F, Artini PG, de Iaco P, Volpe A, de Aloysio D, Battaglia C: Transdermal HRT and Doppler findings in normotensive and hypertensive postmenopausal patients. Ultrasound Obstet Gynecol; 2005 Oct;26(5):546-51
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transdermal HRT and Doppler findings in normotensive and hypertensive postmenopausal patients.
  • OBJECTIVE: To evaluate the effects of transdermal hormone replacement therapy (HRT) on plasma viscosity, serum levels of thromboxane B2 (TXB2) and vascular impedance in the uterine, bladder wall, internal carotid and ophthalmic arteries in normotensive and hypertensive postmenopausal patients.
  • Before starting HRT and after 6 months of therapy, the patients underwent: transvaginal ultrasonographic examination of the pelvic organs; Doppler examination of the blood flow velocities in the uterine, bladder wall, internal carotid and ophthalmic arteries; and analysis of plasma viscosity and plasma TXB2.
  • RESULTS: After 6 months of HRT plasma viscosity had decreased in both groups (mean reduction in Group 1, (14+/-1)%, P=0.005; mean reduction in Group 2, (10+/-1)%, P=0.005) as had the TXB2 levels (mean reduction in Group 1, (93+/-2)%, P<0.001; mean reduction in Group 2, (92+/-3)%, P<0.001).
  • CONCLUSIONS: Our results show that transdermal HRT is effective in reducing plasma viscosity, TXB2 levels and vascular impedance in the peripheral and central vessels both in normotensive and hypertensive postmenopausal patients.
  • [MeSH-major] Estrogen Replacement Therapy. Hypertension / ultrasonography. Postmenopause / blood. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 ISUOG.
  • (PMID = 16184506.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 54397-85-2 / Thromboxane B2; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


9. Griffiths F: Women's control and choice regarding HRT. Soc Sci Med; 1999 Aug;49(4):469-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Women's control and choice regarding HRT.
  • The promotion and use of hormone replacement therapy (HRT) is the focus of much medical activity and a social phenomenon studied by sociology.
  • The decision to prescribe HRT by a doctor may be a response to a woman's distress and is a decision involving uncertainty about risks and benefits.
  • Sociological analysis has seen the promotion and use of HRT as medicalisation of the menopause.
  • Through individual interviews and focus groups, this study hears from women how they approach the decision to take HRT or not, and what influences them.
  • The interviews reveal how women who dislike medication in general may consider HRT, influenced by fear of ill health which may be enhanced by the experience of illness in the family and by medical advice.
  • For the women the media and their social contacts were the major sources of information about HRT.
  • In the focus groups the women explored the control they had over the choice to take HRT and what limited this control and they explored the uncertainties and complexities of the decision to take HRT or not.
  • This study brings lay women's voices to the debate about the use and promotion of HRT.
  • The results are also used to test the limits of the theory of medicalisation and to inform doctors of the issues women may bring to a consultation about HRT.
  • [MeSH-major] Attitude to Health. Decision Making. Estrogen Replacement Therapy / psychology. Patient Participation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10414807.001).
  • [ISSN] 0277-9536
  • [Journal-full-title] Social science & medicine (1982)
  • [ISO-abbreviation] Soc Sci Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  •  go-up   go-down


10. Conlon O, McKinney K: HRT: have we changed? Ir J Med Sci; 2006 Oct-Dec;175(4):58-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HRT: have we changed?
  • BACKGROUND: In recent years, medical controversy, has surrounded the prescribing of hormone replacement therapy (HRT).
  • AIM: This study aimed to establish whether prescribing of HRT in Northern Ireland has changed and what the current prescribing patterns are.
  • RESULTS: Overall 54% of respondents indicated that they had changed their prescribing practice on HRT in the past year.
  • The primary indication for prescribing HRT was vasomotor symptoms (93%).
  • CONCLUSIONS: More than half of all doctors who responded had changed their prescribing practices on HRT, yet some respondents still preferred more traditional prescribing.
  • [MeSH-major] Attitude of Health Personnel. Estrogen Replacement Therapy / trends. Practice Patterns, Physicians'
  • [MeSH-minor] Complementary Therapies. Female. Humans. Northern Ireland. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 Aug 18;282(7):637-45 [10517716.001]
  • [Cites] JAMA. 2003 Oct 1;290(13):1729-38 [14519707.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2002 Jun;16(3):293-307 [12099664.001]
  • [Cites] Am J Obstet Gynecol. 2002 Apr;186(4):717-22 [11967497.001]
  • [Cites] Endocr Rev. 2002 Feb;23(1):16-37 [11844743.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5700-5 [11739424.001]
  • [Cites] JAMA. 2002 Jul 17;288(3):321-33 [12117397.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):419-27 [12927427.001]
  • [Cites] J Clin Invest. 1997 Sep 15;100(6):1475-80 [9294113.001]
  • [Cites] J Br Menopause Soc. 2002 Dec;8(4):129 [12804318.001]
  • (PMID = 17312831.001).
  • [ISSN] 0021-1265
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down






Advertisement